IN VITRO ANTIMICROBIAL ACTIVITY OF CEFODIZIME (THR-221) AND CLINICAL EVALUATION IN RESPIRATORY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement5; pp. 329 - 338
• Main Authors: AONUMA, SEIICHI, TOKUE, YUTAKA, KITAMURA, NAOTO, HONDA, YOSHIHIRO, ONO, REIKO, WATANABE, AKIRA, SASAKI, MASAKO, OIZUMI, KOTARO, KONNO, KIYOSHI, NAGAI, KOSAKU
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement5_329

In vitro antimicrobial activity of cefodizime (THR-221), a new cephalosporin, was examined by broth-dilution method using the MIC-2000 system. The minimum inhibitory concentrations (MICs) for THR-221 against 170 clinical isolates were compared with those for cefotaxime (CTX), cefoperazone (CPZ) and Iatamoxef (LMOX). Against all isolates tested, THR-221 was less active than CTX. THR-221 was more active than LMOX against S. aureus and Proteus spp., and less active than CPZ against S. aureus, E. cloacae and P. aeruginosa. THR-221 was administered to 18 patients with respiratory tract infection by drip infusion. Clinical response was excellent in 1, good in 12, fair in 1 and poor in 2; 2 cases were not evaluable. Adverse reactions and abnormal laboratory levels were: skin rash, urticaria, diarrhea, eosinophilia and thrombocytopenia in one case each.